Cybin Forum: Community User: Mexxx007

Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program

:D. da ist der Ballon

🎈

https://ir.cybin.com/investors/news/news-details/2023/Cybin-Inc.-Reports-Third-Quarter-Financial-Results-and-Recent-Business-Highlights/default.aspx

https://ir.cybin.com/investors/news/news-details/2023/Cybin-Announces-Approval-of-First-in-Human-Dosing-of-its-Proprietary-DMT-Molecule-CYB004/default.aspx

Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004

jetzt sollte mal wieder ein Gegenbewegung kommen - das Ganze verpufft wieder - 7 Analysten positiv - jedoch merkt man nicht so viel seit 1 Jahr -

Ein Trauerspiel. Sämtliche Katalysts verpuffen. BioTech-Aktie halt. Wundern sollte man sich da nicht. Werde ein letztes Mal den EK senken. Beim nächsten Pump bin ich raus. Geldgefängnis.

weiter positiv

war ein netter Ausbruchsversuch - aber anscheinend mehr nicht -

und runter gehts :D

läuft

abeni - was denkst du =00= > bald

Cybin erhält Exklusivlizenz für einen neuartigen Katalog psychedelisch wirksamer Verbindungen

cybininc: Cybin is pleased to announce that the first two participants have been dosed in our Phase 1/2a trial evaluating CYB003 for the treatment of Major Depressive Disorder (MDD). "To commence dosing in our first-in-human Phase 1/2a trial is a tremendous milestone for Cybin, especially having reached the clinic within just 18 months. Our goal continues to focus on becoming a leader in creating the best psychedelic therapies for patients and today we have moved one step closer," said CEO Doug Drysdale. "Through our rigorous preclinical work and ongoing clinical development of CYB003, we believe we have the potential to unlock the powerful benefits of psilocybin for the treatment of MDD without its well-known limitations."

https://ir.cybin.com/investors/news/news-details/2022/Cybin-Inc.-Reports-Fiscal-Year-2022-Financial-Results-and-Recent-Business-Highlights/default.aspx